Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

tent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... The laboratory information management systems market is ... of technological advancements due to factors such as rising ... integrate healthcare systems, and increasing government support for adoption ... Key players in the market focus on technological advancements ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... 19 New long-term data from two pivotal, Phase ... arthritis (RA) receiving SIMPONI (TM) (golimumab) every four ... physical function response through one year. These new ... of Rheumatology (ACR) Annual Scientific Meeting. , "New data ...
... , QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna ... (the "Company"), a global biopharmaceutical company focused on ... has initiated activities intended to complete the clinical ... ghrelin agonist compound macimorelin (AEZS-130) which could be ...
... Holdings, Inc. ("Cellu Tissue") today announced that it has filed a ... Commission (the "SEC") relating to a proposed initial public offering of ... shares to be sold by Cellu Tissue and shares to be ... shares to be offered, the allocation of shares to be sold ...
Cached Biology Technology:New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 2New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 3New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 4New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 5New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 6New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 7New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 8New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 9New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 10AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... births resulting from in-vitro-fertilization (IVF), researchers at Yale School ... that estimates the reproductive potential of individual embryos, possibly ... higher success rate in women undergoing IVF. , Over ... the United States. In 2002, 3.1 embryos on average ...
... approach can kill bacteria in laboratory experiments and eliminate ... bacterial nutrient, according to research led by a University ... UW, the University of Iowa, and the University of ... of the Journal of Clinical Investigation. , Bacteria ...
... of light are providing insight into the complexities of the ... of how the human brain works. , Investigators at Duke ... engineered a strain of mice whose olfactory brain cells "fire" ... the cells a gene naturally present in green algae that ...
Cached Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
... family of calcium binding proteins such as calmodulin ... an alpha and beta chain whereas S100B is ... is also expressed in the antigen presenting cells ... interdigitating reticulum cells in the paracortex of lymph ...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Polyclonal Antibody to AHI1 / Jouberin...
Biology Products: